ArticleThe Journal of clinical investigation1992
Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody.
Article in The Journal of clinical investigation, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 51 citations in OpenAlex.
- Priming antibody responses to the fusion peptide in rhesus macaques.NPJ vaccines · 2024Article
- Ig Constant Region Effects on Variable Region Structure and Function.Frontiers in microbiology · 2016Review
- Vectored antibody gene delivery for the prevention or treatment of HIV infection.Current opinion in HIV and AIDS · 2015Review
- Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.Biochemical and biophysical research communications · 2009Article
- Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.Molecular immunology · 2009Article
- T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120.Gene therapy · 2005Article
- Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes.Gene therapy · 2002Article
- Molecular determinants of the human antibody response to HIV-1: implications for disease control.Journal of clinical immunology · 2001Article
- Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17.Molecular medicine (Cambridge, Mass.) · 1997Article
- Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor.Proceedings of the National Academy of Sciences of the United States of America · 1995Article
- Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies.The EMBO journal · 1995Article
- The molecular structure of human antibodies specific for the human immunodeficiency virus.Journal of clinical immunology · 1995Review
- Variable region sequences of a protective human monoclonal antibody specific for the Haemophilus influenzae type b capsular polysaccharide.Infection and immunity · 1994Article
- Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody.Proceedings of the National Academy of Sciences of the United States of America · 1994Article
- Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody.Proceedings of the National Academy of Sciences of the United States of America · 1993Article
- Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.Proceedings of the National Academy of Sciences of the United States of America · 1993Article
- Content and dynamics of the human antibody variable region repertoire to the Haemophilus influenzae type b polysaccharide.Springer seminars in immunopathology · 1993Review
- Nonrandom features of the human immunoglobulin variable region gene repertoire expressed in response to HIV-1.Applied biochemistry and biotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
The F105 mAb, identified in an HIV-1-infected individual, binds to a discontinuous epitope on the HIV-1 gp120 envelope glycoprotein, blocks the binding of gp120 to the CD4 viral receptor, and neutralizes a broad range of HIV-1 isolates. This study reports the primary nucleotide and deduced amino acid sequences of the rearranged heavy and light chains of the mAb F105. This IgG1k mAb uses a VH gene member of the VH4 gene family (V71-4) and is productively rearranged with a D-D fusion product of the dlr4 and da4 germline DH genes and the JH5 gene. This rearranged heavy chain gene expresses the VH4-HV2a idiotope, which is seen in human monoclonal IgM cold agglutinins. The F105 Vk appears to be derived from the Humvk325 germline gene and is rearranged with a Jk2 gene. For both chains, the mutational pattern in the rearranged VH and VL genes is indicative of an antigen-driven process. These studies show that production of a broadly neutralizing anti-HIV-1 antibody that recognizes determinants within the CD4 recognition site of the envelope glycoprotein is achieved by rearrangement of the V71-4 and Humvk325 germline variable region genes along with selected individual point mutations in the rearranged genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.